莫沙比利联合埃索美拉唑镁肠溶片治疗老年慢性萎缩性胃炎的疗效

Efficacy of mosapride combined with esomeprazole magnesium enteric-coated tablets in the treatment of elderly patients with chronic atrophic gastritis

目的 探讨莫沙比利联合埃索美拉唑镁肠溶片治疗老年慢性萎缩性胃炎(CAG)患者疗效及对胃动力水平、胃黏膜前列腺素E2(PGE2)水平的影响。方法 选取2021年1月—2022年1月本院收治的146例老年CAG患者,按数字表法随机分为观察组(n=74)和对照组(n=72)。对照组服用莫沙比利,观察组在此基础上服用埃索美拉唑镁肠溶片。比较两组治疗前后胃动力水平(餐前与餐后胃电图幅值、胃泌素)、胃黏膜PGE2、炎性因子[白介素6(IL-6)、白介素8(IL-8)、肿瘤坏死因子α(TNF-α)]、临床疗效、症状消失时间及不良反应。结果 观察组总有效率明显高于对照组(P<0.05);观察组腹胀消失时间、疼痛消失时间明显短于对照组(P<0.05);观察组治疗后餐前与餐后胃电图幅值、胃泌素水平明显高于对照组(P<0.05);观察组治疗后胃黏膜PGE2水平明显高于对照组(P<0.05);观察组治疗后IL-6、IL-8、TNF-α水平明显低于对照组(P<0.05);两组不良反应总发生率比较无显著差异(P>0.05)。结论 莫沙比利联合埃索美拉唑镁肠溶片可有效提高老年CAG患者胃动力水平及胃黏膜PGE2水平,减轻机体炎症,促进临床症状消失,获得更好疗效,且不良反应少。

Objective To observe the efficacy of mosapride combined with esomeprazole magnesium enteric-coated tablets in the treatment of elderly patients with chronic atrophic gastritis(CAG),and the influence on gastric motility and gastric mucosa prostaglandin E2(PGE2)level.Methods A total of 146 elderly patients with CAG admitted to the hospital from January 2021 to January 2022 were selected,and divided into 2 groups by random number table method.Patients in control group took mosapride,and those in observation group took esomeprazole magnesium enteric-coated tablets on this basis.The two groups were compared in terms of gastric motility(electrogastrogram amplitudes and gastrin levels before and after the meal),gastric mucosa PGE2,inflammatory factors[interleukin 6(IL-6),interleukin 8(IL-8)and tumor necrosis factor alpha(TNF-α)],clinical effect,symptom disappearing time,and adverse reactions.Results The total response rate in observation group was significantly higher than that in control group(P<0.05).The disappearance time of abdominal distension and pain in observation group was significantly shorter than that in control group(P<0.05).After treatment,electrogastrogram amplitudes and gastrin levels before and after the meal in observation group were significantly greater/higher than those in control group(P<0.05).After treatment,gastric mucosa PGE2 level in observation group was significantly higher than that in control group,and the levels of IL-6,IL-8 and TNF-αwere significantly lower than those in control group(all P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Mosapride combined with esomeprazole magnesium enteric-coated tablets can effectively improve gastric motility and gastric mucosa PGE2 level in elderly patients with CAG,relieve inflammation,and promote the disappearance of clinical symptoms,with a few adverse reactions.